Sugi Predict

Sugi Predict / Compounds / SCHEMBL7689552

SCHEMBL7689552

SCHEMBL7689552

O=C(O)c1ccc2nccc(Cl)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.48
▸ MAPKAPK2 P49137 1/20 0.48
▸ KMO O15229 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ MAPT P10636 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ KDM6B O15054 1/20 0.46
▸ TET3 O43151 1/20 0.46
▸ KDM4A O75164 1/20 0.46
▸ BBOX1 O75936 1/20 0.46
▸ KDM5A P29375 1/20 0.46
▸ KDM5C P41229 1/20 0.46
▸ ASPH Q12797 1/20 0.46
▸ KDM4D Q6B0I6 1/20 0.46
▸ TET2 Q6N021 1/20 0.46
▸ ALKBH5 Q6P6C2 1/20 0.46
▸ KDM7A Q6ZMT4 1/20 0.46
▸ KDM8 Q8N371 1/20 0.46
▸ TET1 Q8NFU7 1/20 0.46
▸ EGLN2 Q96KS0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1732368 0.86 SMYD3 (0.49) TSHRMAPKAPK2KMOALDH1A1MAPT
SCHEMBL22113898 0.86 DOT1L (0.41) MAPKAPK2ALDH1A1MAPTKDM4ENAPRT
SCHEMBL15043774 0.85 SLC2A1 (0.53) MAPKAPK2ALDH1A1MAPTKDM4EL3MBTL1
SCHEMBL7230935 0.85 MAP4K4 (0.43) MAPKAPK2KDM4EIP6K1DOT1L
SCHEMBL5757121 0.82 MAPKAPK2 (0.45) MAPKAPK2MAPTL3MBTL1NPC1RAB9A
SCHEMBL9907387 0.82 MAPKAPK2 (0.45) TSHRMAPKAPK2KMOALDH1A1MAPT
SCHEMBL29318229 0.81 CLK4 (0.46) TSHRALDH1A1HSD17B10LMNAPOLB
SCHEMBL27159840 0.81 PLK1 (0.56) TDP1NPC1RAB9AIP6K1IP6K3
SCHEMBL1299987 0.81 ALOX15 (0.56) ALDH1A1KDM4EKDM6BKDM5CKDM4C
SCHEMBL10464811 0.81 LMNA (0.62) MAPKAPK2ALDH1A1MAPTKDM4EKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 — — US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 — — CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 — — US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 — — US disclosed
US-11597728-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-03-07 — — US disclosed
US-20220315583-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 — — US disclosed
EP-3856179-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica N.V. (BE) 2021-08-04 — — EP disclosed
CN-113164458-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 — — CN disclosed
WO-2020065614-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 — — WO disclosed
US-8710043-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2014-04-29 — — US disclosed
US-8710043-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2014-04-29 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed
WO-2012177893-A2 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2012-12-27 — — WO disclosed
WO-2012177893-A2 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2012-12-27 — — WO disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 — — WO disclosed
US-4396620-A BACTERICIDES ELI LILLY AND COMPANY (US) 1983-08-02 — — US disclosed
US-4382931-A 3'-Substituted quinolinium cephalosporins ELI LILLY AND COMPANY (US) 1983-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TSHR 1194/4885MAPKAPK2 2807/4885KMO 615/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TSHR 1194/4885MAPKAPK2 2807/4885KMO 615/4885
US-11597728-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP TSHR 1194/4885MAPKAPK2 2807/4885KMO 615/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TSHR 1194/4885MAPKAPK2 2807/4885KMO 615/4885
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 TSHR 2647/4885MAPKAPK2 1025/4885KMO 1264/4885
US-20220315583-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP TSHR 1194/4885MAPKAPK2 2807/4885KMO 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.